We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pt15.0
PT-141 Research
Mostly mechanism / observationalLimited safety
25 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most PT-141 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2003–2026 with a typical study size of 397 participants.
Based on 25 studies · 2 meta-analyses · 5 RCTs · 4,752 total participants
Confidence
High
By outcome
Sexual desire & HSDD
Mostly mechanism / observational18 studies
Erectile function (earlier ED trials)
Mostly mechanism / observational7 studies
Safety profile
Mostly mechanism / observational5 studies
Heart & blood pressure
Too few graded studies1 study
Weight management
Too few graded studies1 study
Active research area
17 studies in the last 5 years · Latest meta-analysis: 2026
200320142026
1Systematic Reviewn=20 · very small study2026
While FDA-approved agents demonstrate clinical potential, investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.
Mavrych V, Shypilova I, Bolgova O. · Frontiers in aging (2026)
Non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation.
Significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy.
Conclusion Therapeutic peptides offer mechanistically diverse approaches to multiple aging hallmarks.
Although this paper explores only a biopsychosocial explanation for the phenomenon of mercy sex in clinical trials of HSDD therapies, it provides a valuable understanding that will benefit patients, clinicians, and researchers.
Guptan N, Simon JA. · Journal of sex & marital therapy (2026)
Baseline data were assessed across time, age, reproductive status, and geography.
Women in these studies engaged in "mercy sex" about 2.5 times/month despite their documented HSDD.
Although this paper explores only a biopsychosocial explanation for the phenomenon of mercy sex in clinical trials of HSDD therapies, it provides a valuable understanding that will benefit patients, clinicians, and researchers.
Although evidence suggests potential benefits, large-scale clinical trials are needed to establish safety profiles, optimal dosing regimens, and possible synergistic effects with existing ED treatments.
Ila V, Pozzi E, Gamage M, Ramasamy R. · Expert opinion on pharmacotherapy (2025)
The literature search utilized PubMed to identify relevant English-language publications up to October 2024, emphasizing studies from the past decade.
Expert opinion IV peptides and amino acids offer promising therapeutic options for ED through mechanisms of action distinct from PED5 inhibitors.
PT-141 and PnPP-19 show efficacy through central nervous system activation and nitric oxide regulation, while L-arginine and L-citrulline enhance endothelial function.
Pharmacists are encouraged to embrace this opportunity to provide premenopausal HSDD care in ambulatory and community practice settings.
Barakeh D, Mdaihly H, Karaoui LR. · The Annals of pharmacotherapy (2025)
Validated tools and objective measures inform tailored premenopausal HSDD care plans and aid in striking a balance between potential risks and adverse effects while maximizing meaningful clinical benefits, including for transgender individuals.
Conclusions Clinicians must discern important distinctions between flibanserin, bremelanotide, and other agents when managing premenopausal HSDD.
Further research with the most suitable clinical endpoints and consideration of patient factors are crucial before widespread adoption of flibanserin and bremelanotide.
This review provides clinicians with relevant considerations to assess when recommending these therapies for patients with breast cancer, while awaiting ongoing research to give additional insights for best tailoring therapy for this patient population.
Fuhrman J, Yun J, Indorf A. · Expert review of clinical pharmacology (2025)
Fezolinetant is a novel neurokinin 3 receptor antagonist that has demonstrated clinical benefit in patients without a history of breast cancer.
For libido management, flibanserin and bremelanotide act as serotonin/dopaminergic modulators and melanocortin receptor agonists, respectively.
Expert opinion These novel agents are eagerly awaited therapeutic options; however, clinical trials excluded breast cancer patients.
Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side effect management, and patient education, improving treatment outcomes and patient satisfaction.
How A, Jowdy C, Novatcheva E, Clayton AH. · Clinical obstetrics and gynecology (2025)
This review evaluates pharmacologic treatments for female sexual dysfunction (FSD), focusing on hypoactive sexual desire disorder (HSDD).
We provide clinically relevant applications for Food and Drug Administration (FDA)-approved medications (flibanserin and bremelanotide) and investigational therapies (Lorexys and testosterone combinations).
Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side effect management, and patient education, improving treatment outcomes and patient satisfaction.
Therefore, this review aims to summarize the function and genetic polymorphism of melanocortin receptors, regulatory pathways involving MCRs, and the existing evidence of the prime effect of MCRs on inflammatory responses via different mechanisms and their potential therapeutic use in inflammatory diseases.
Bardhan M, Anand A, Javed A, Chilo MA, Khan N, Garg T, Surana A, Huang H, Samim MM, Suresh V, Khare A, Menon B, Kundu T. · Diseases (Basel, Switzerland) (2025)
Among them, α-MSH analogs play a role in atopic dermatitis and scleroderma, and MC1R agonist Dersimelagon has shown effectiveness in systemic sclerosis.
The FDA has recently approved the repository corticotropin injection (RCI) to treat sarcoidosis.
The FDA has also approved various melanocortin agonists, i.e., Bremelanotide, Afamelanotide, and Setmelanotide, for the treatment of hypoactive sexual desire disorder, Erythropoietic protoporphyria, and obesity, due to pro-opiomelanocortin and leptin receptor deficiency, respectively.
Awareness of PMDD and FSD among clinicians and society can allow the implementation of targeted interventions to alleviate the suffering of women and enhance their quality of life.
Gollapudi M, Thomas A, Yogarajah A, Ospina D, Daher JC, Rahman A, Santistevan L, Patel RV, Abraham J, Oommen SG, Siddiqui HF. · Cureus (2024)
Studies show that women frequently experience debilitating sexual distress during the premenstrual phase; however, there is an essential need to formulate standardized tools for definite diagnosis.
Selective serotonin re-uptake inhibitors (SSRIs) and combined oral contraceptive pills (COCPs) are approved medications for PMDD, while flibanserin and bremelanotide are effective in treating FSD.
However, the potential effects of these treatment modalities on the two comorbid conditions render them inconclusive.
Women taking bremelanotide had statistically significant increases in sexual desire and statistically significant reductions in distress related to low sexual desire compared with placebo.
Kingsberg SA, Clayton AH, Portman D, et al. · Obstet Gynecol (2019)
Two identical phase-3, randomized, double-blind, placebo-controlled, multicenter trials (RECONNECT) of bremelanotide 1.75 mg subcutaneously as-needed over 24 weeks
1,267 premenopausal women with HSDD randomized 1:1 (mean age 39)
Met coprimary endpoints: significant gains in FSFI desire-domain score (integrated +0.35, P<.001) and reduced desire-related distress (integrated -0.33, P<.001) vs placebo
As peptide therapeutics continue to evolve, d-amino acids-containing drugs are poised to play a central role in the next generation of targeted, stable, and high-precision pharmaceuticals.
Tran L, Nguyen TD, Gad AG, Shaaban E, Tai TH, Tram NT, Nguyen Khanh Tran H, Le MT, Huy NT. · Drug development research (2026)
Since the mid-20th century, more than 20 FDA-approved drugs have incorporated at least one d-amino acid into their structure, spanning indications from infectious diseases and endocrine disorders to rare dermatologic conditions and diagnostic imaging.
These drugs include both natural products like gramicidin D and synthetic analogs such as desmopressin, leuprolide, bremelanotide, and etelcalcetide, the latter being the first fully d-amino acid peptide to receive FDA approval.
As peptide therapeutics continue to evolve, d-amino acids-containing drugs are poised to play a central role in the next generation of targeted, stable, and high-precision pharmaceuticals.
Additional research is needed on pharmacological interventions and types of counselling to strengthen their evidence.
Bhinder JK, Kennedy SKF, Faouk Al Aadah C, Al-Khaifi M. · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025)
ASCO recommends any kind of stimulation (including masturbation) to improve sexual response, while NCCN and SOGC recommend the use of sexual aids (e.g., vibrators) to enhance arousal.
Although all guidelines, except ESO-ESMO, include recommendations for androgens, bupropion, flibanserin, bremelanotide, and buspirone for low sex drive, there is limited data.
Conclusion There is consensus among guidelines on certain sexual health recommendations, with some variation.
Across RECONNECT trial data from two prior publications and the current study, bremelanotide's benefits are statistically modest and limited to outcomes for which scant evidence of validity among women with HSDD exists.
Spielmans GI, Ellefson EM. · Journal of sex research (2024)
We analyzed these outcomes, upon which effect sizes ranged from nil to small.
All efficacy results should be reported, but results on 8 of the 11 clinicaltrials.gov-specified efficacy outcomes were heretofore unpublished (including FSDS-DAO total score, FSFI total score, FSFI arousal domain, and items from the Female Sexual Encounter Profile-Revised).
Several other continuous and categorical outcomes generated modest apparent benefits, though nearly all of these outcomes were likely derived post-hoc.
Responder analyses... were used to determine whether changes... are clinically meaningful... in a large, controlled, phase 2b, dose-finding study of bremelanotide in premenopausal women with HSDD.
Althof S, Derogatis LR, Greenberg S, et al. · J Sex Med (2019)
Phase-2b, randomized, controlled dose-ranging study in premenopausal women with HSDD and mixed HSDD/FSAD
Derived minimal clinically important differences (MCIDs) for desire and distress endpoints
Established the dose and responder framework carried into the phase-3 RECONNECT trials
Increases in ambulatory SBP relative to placebo of... 3.1 and 3.2 mmHg (1.75 mg)... occurred following two doses... peak increases typically lasted less than 15 min.
White WB, Myers MG, Jordan R, et al. · J Hypertens (2017)
Randomized, double-blind, placebo-controlled ambulatory-BP trial of bremelanotide (0.75/1.25/1.75 mg) in 397 premenopausal women with FSD (normotensive or controlled-hypertensive)
Small, transient increases in systolic and diastolic BP (peaks typically <15 min) with reflex heart-rate reduction (-4.6 to -4.7 bpm at 1.75 mg)
26 participants discontinued for prespecified BP increases (similar across arms)
flibanserin improves desire; and bremelanotide improves both desire and arousal; and all 3 treatments reduce distress.
Toledo RG, Winkelman WD, Reyes-Gonzalez D, Bergeron S, Fladger A, Hacker MR, Anand M. · J Minim Invasive Gynecol (2026)
Systematic review and meta-analysis of treatments for female sexual desire/arousal/orgasm dysfunction (36 studies, 26 RCTs); meta-analyses were conducted for mindfulness-based CBT, flibanserin and bremelanotide
Bremelanotide significantly improved total FSFI and its desire and arousal subscales vs placebo
Bremelanotide (like flibanserin and CBT) reduced sexual distress
Positive clinical results were seen in 51 (33.5%) patients in the bremelanotide group compared with 13 (8.5%) patients in the placebo group.
Safarinejad MR, Hosseini SY. · J Urol (2008)
Randomized, double-blind, placebo-controlled trial of INTRANASAL bremelanotide 10 mg in 342 men with erectile dysfunction who did not respond to sildenafil
Positive clinical results in 33.5% (bremelanotide) vs 8.5% (placebo); greater intercourse satisfaction
More drug-related adverse effects in the bremelanotide group